Hydroxynorketamine
Hydroxynorketamine (HNK), or 6-hydroxynorketamine, is a minor metabolite of the anesthetic, dissociative, and antidepressant drug ketamine. It is formed by hydroxylation of the intermediate norketamine, another metabolite of ketamine. As of late 2019, (2R,6R)-HNK is in clinical trials for the treatment of depression.
The four possible stereoisomers of Hydroxynorketamine | |||
Clinical data | |||
---|---|---|---|
Other names | HNK; 6-Hydroxynorketamine; 6-HNK | ||
ATC code |
| ||
Identifiers | |||
| |||
CAS Number | |||
PubChem CID | |||
ChemSpider | |||
UNII | |||
CompTox Dashboard (EPA) | |||
Chemical and physical data | |||
Formula | C12H14ClNO2 | ||
Molar mass | 239.70 g·mol−1 | ||
3D model (JSmol) | |||
SMILES
| |||
|
The major metabolite of ketamine is norketamine (80%). Norketamine is secondarily converted into 4-, 5-, and 6-hydroxynorketamines (15%), mainly HNK (6-hydroxynorketamine). Ketamine is also transformed into hydroxyketamine (5%). As such, bioactivated HNK comprises less than 15% of a dose of ketamine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.